Alto Neuroscience, Inc.
NYSE:ANROBiotechnology
Healthcare
$25.91 +1.84%
+$0.40 today
- Market cap
- $1.04B
- Beta
- 1.25
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$2.26
52W Low $2.15High $28.44
Volume 0.99M
Average 0.34M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$51.77M
FY 2025 · Annual
Investing Cash Flow
-$24,000.00
FY 2025 · Annual
Financing Cash Flow
$60.08M
FY 2025 · Annual
-55.7% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Depreciation & Amortization | 145K | 342K | 373K | 502K | 661K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 227K | 1.76M | 2.89M | 7.63M | 8.11M |
| Change in Working Capital | (572K) | 4.58M | (698K) | 4.06M | 33K |
| Accounts Receivables | (1.29M) | 1.16M | 325K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 458K | 1.01M | (632K) | 516K | 221K |
| Other Working Capital | 255K | 2.42M | (391K) | 3.54M | (188K) |
| Other Non-Cash Items | 125K | 632K | 291K | 1.81M | 2.67M |
| Operating Cash Flow | (9.26M) | (20.39M) | (33.45M) | (47.42M) | (51.77M) |
| Capital Expenditures | (680K) | (732K) | (470K) | (2.08M) | (24K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (680K) | (732K) | (470K) | (2.08M) | (24K) |
| Debt Repayment | 0 | 9.83M | 0 | 1.25M | 9.48M |
| Common Stock Issued | 7K | 43K | 181K | 137.58M | 50.7M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (167K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (205K) | (341K) | (2.05M) | (3.14M) | 67K |
| Financing Cash Flow | 31.69M | 43.79M | 68.13M | 135.69M | 60.08M |
| Effect of Forex Changes | (50K) | (24K) | (8K) | (11K) | (30K) |
| Net Change in Cash | 21.7M | 22.64M | 34.2M | 86.18M | 8.26M |
| Free Cash Flow | (9.94M) | (21.13M) | (33.92M) | (49.5M) | (51.79M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$63.2M
+ D&A$661.0K
+ Stock-Based Comp$8.1M
+ Deferred Tax$0
+ Working Capital$33.0K
+ Other Non-Cash$2.7M
= Operating Cash Flow-$51.8M
- Capex-$24.0K
= Free Cash Flow-$51.8M
Analysis
FY2025 free cash flow is -$51.8M. FCF conversion is 81.9% of net income. Operating cash flow was -$51.8M, with capex of -$24.0K. The largest bridge item is Stock-Based Comp at $8.1M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13G | SC 13G filing | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 1, 2026 |
Does ANRO generate free cash flow?
Alto Neuroscience, Inc. (ANRO) generated -$51.79M of free cash flow in fiscal 2025.
How much operating cash flow does ANRO produce?
Operating cash flow was -$51.77M, before capital expenditures of $24,000.00.
Continue the stock analysis
Jump to another research area for this company.